The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound, or enantiomers, stereoisomers and tautomers thereof, or pharmaceutically acceptable salts or solvates of said compound, with said compound having the general structure shown in Formula I:

B'



Formula I

wherein M is a moiety of the formula:



~~having a general structure shown in Formula II:~~



II

where k = 0 or 1, and n = 0-5 [[, and p = q = 0, 1 or 2]];

V is a moiety selected from the group consisting of C_1-C_8 alkyl; $-(CH_2)_x-A-(CH_2)_y-$; and $-(CH_2)_c-A-(CH_2)_m-C(O)-N(R^7)-(CH_2)_d-$, where A is -O-, $-S(O)_r-$, and $-NR^7-$;

m = 0, 1, 2 or 3; x is a whole number in the range 2-8; y is a whole number in the range 1-5; c is a whole number in the range 2-4; and r= 0, 1 or 2; d is a number in the range 0-5;

[[X and Y are independently selected from the group consisting of N, and CH;]]

one of X is N and the other is CH;

[[Z and Z^1 can be the same or different, each being independently selected from the group consisting of N, CH and N(O);]]

R^1 and R^2 may each number 1-4 and are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, polyhalolower alkyl, polyhalolower alkoxy, -OH, CN, NO_2, or $COOR^8$;

R^3 is selected from hydrogen, lower alkyl, lower alkoxy, hydroxyl~~, with the proviso that when n and k are both 0, then R^3 is not -OH or alkoxy~~;

R^4 is selected from the group consisting of hydrogen, lower alkyl, polyhalolower alkyl or -OH; and

R^7 and R^8 are independently selected from hydrogen, lower alkyl, substituted or unsubstituted phenyl; and substituted or unsubstituted benzyl, wherein said term "substituted" means optional substitution from one or more moieties selected from the group consisting of alkyl, alkoxy, $-CF_3$, halogen or aryl.

Claim 2 (original): The compound of claim 1, wherein R^4 is H.

Claim 3 (original): The compound of claim 2, wherein R^1 and R^2 are independently selected from H, halogen, or polyhalolower alkyl.

Claim 4 (canceled).

Claim 5 (amended): The compound of claim 1, wherein M is a piperazine. [[:



and p = q = 1.]]

Claim 7 (original): The compound of claim 1, wherein M is piperidine, R^4 is H; R^1 = R^2 = H, halogen, hydroxy or alkoxy; and R^3 is H or lower alkyl.

Claim 8 (original): The compound of Claim 6, wherein V = $C_1 - C_8$ alkyl.

Claim 9 (original): The compound of claim 5, wherein R^4 is H; and R^1 = R^2 = H, halogen, hydroxy or alkoxy.

Claim 10 (original): The compound of Claim 8, wherein V is $C_1 - C_8$ alkyl.

Claim 11 (previously amended): A pharmaceutical composition comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 11 (previously canceled).

Claim 12 (previously canceled).

Claim 13 (currently amended): A method of treating airway and gastrointestinal disorders ~~inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity~~, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 1.

Claim 14 (previously canceled).

Claim 15 (currently Amended): A method of preparing a pharmaceutical composition for treating airway and gastrointestinal disorders ~~inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity~~, said method comprising bringing into intimate contact a compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 16 (currently amended): A compound exhibiting H_3 antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:






Claim 17 (currently amended): A compound exhibiting both H_1 and H_3 antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:












Claim 18 (currently amended): A pharmaceutical composition for treating airway and gastrointestinal disorders ~~inflammation, allergy, nasal congestion, diseases of the GI tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy induced airway responses, and obesity~~, said composition comprising therapeutically effective amount of a compound of claim 16 or claim 17 and a pharmaceutically acceptable carrier.

Claims 19-21 (canceled).

Claim 22 (new): The compound of claim 1, wherein M is a piperidine.

Claim 23 (new): The compound of claim 1, wherein M is a pyrrolidine.